ArticleInfection and immunity2006
A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice.
Article in Infection and immunity, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 69 citations in OpenAlex.
- Article
- Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi.Archives of microbiology · 2024Review
- Human-Fungal Pathogen Interactions from the Perspective of Immunoproteomics Analyses.International journal of molecular sciences · 2024Review
- The Host Response to Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Fungal Vaccine Development: State of the Art and Perspectives Using Immunoinformatics.Journal of fungi (Basel, Switzerland) · 2023Review
- Application of anti-fungal vaccines as a tool against emerging anti-fungal resistance.Frontiers in fungal biology · 2023Review
- Antibody screening reveals antigenic proteins involved inFrontiers in cellular and infection microbiology · 2023Article
- Challenges in Serologic Diagnostics of Neglected Human Systemic Mycoses: An Overview on Characterization of New Targets.Pathogens (Basel, Switzerland) · 2022Review
- Characterization of the Growth and Morphology of a BSL-2Journal of fungi (Basel, Switzerland) · 2022Article
- Current Landscape of Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Key thermally dimorphic fungal pathogens: shaping host immunity.Open biology · 2022Review
- A Review ofCurrent clinical microbiology reports · 2021Review
- Advances in Fungal Peptide Vaccines.Journal of fungi (Basel, Switzerland) · 2020Review
- The Rise ofFrontiers in immunology · 2019Review
- Secreted aspartyl proteinase (PbSap) contributes to the virulence of Paracoccidioides brasiliensis infection.PLoS neglected tropical diseases · 2018Article
- Coccidioides immitis and posadasii; A review of their biology, genomics, pathogenesis, and host immunity.Virulence · 2018Review
- Immune Response to Coccidioidomycosis and the Development of a Vaccine.Microorganisms · 2017Review
- The Quest for a Vaccine Against Coccidioidomycosis: A Neglected Disease of the Americas.Journal of fungi (Basel, Switzerland) · 2016Review
- Aspartyl Proteinases of Eukaryotic Microbial Pathogens: From Eating to Heating.PLoS pathogens · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Coccidioidomycosis is a respiratory disease of humans caused by the desert soil-borne fungal pathogens Coccidioides spp. Recurrent epidemics of this mycosis in the southwestern United States have contributed significantly to escalated health care costs. Clinical and experimental studies indicate that prior symptomatic coccidioidomycosis induces immunity against subsequent infection, and activation of T cells is essential for containment of the pathogen and its clearance from host tissue. Development of a human vaccine against coccidioidomycosis has focused on recombinant T-cell-reactive antigens which elicit a durable protective immune response against pulmonary infection in mice. In this study we fractionated a protective multicomponent parasitic cell wall extract in an attempt to identify T-cell antigens. Immunoblots of electrophoretic separations of this extract identified patient seroreactive proteins which were subsequently excised from two-dimensional polyacrylamide gel electrophoresis gels, trypsin digested, and sequenced by tandem mass spectrometry. The full-length gene which encodes a dominant protein in the immunoblot was identified using established methods of bioinformatics. The gene was cloned and expressed, and the recombinant protein was shown to stimulate immune T cells in vitro. The deduced protein was predicted to contain epitopes that bind to human major histocompatibility complex class II molecules using a TEPITOPE-based algorithm. Synthetic peptides corresponding to the predicted T-cell epitopes induced gamma interferon production by immune T lymphocytes. The T-cell-reactive antigen, which is homologous to secreted fungal aspartyl proteases, protected mice against pulmonary infection with Coccidioides posadasii. We argue that this immunoproteomic/bioinformatic approach to the identification of candidate vaccines against coccidioidomycosis is both efficient and productive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.